Cargando…
Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy
Direct-acting antivirals (DAAs) for hepatitis C virus (HCV) may induce hepatitis B virus (HBV) reactivations in co-infected patients, whose dynamics and outcomes could depend on the phase of HBV infection. We investigated HBsAg and HBV-DNA kinetics in fifteen untreated HBeAg Negative Infection (ENI)...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911219/ https://www.ncbi.nlm.nih.gov/pubmed/35268497 http://dx.doi.org/10.3390/jcm11051406 |
_version_ | 1784666736760455168 |
---|---|
author | Colombatto, Piero Palmisano, Elena Ricco, Gabriele Cavallone, Daniela Oliveri, Filippo Coco, Barbara Salvati, Antonio Romagnoli, Veronica Surace, Lidia Vatteroni, Marialinda Pistello, Mauro Virdis, Agostino Bonino, Ferruccio Brunetto, Maurizia Rossana |
author_facet | Colombatto, Piero Palmisano, Elena Ricco, Gabriele Cavallone, Daniela Oliveri, Filippo Coco, Barbara Salvati, Antonio Romagnoli, Veronica Surace, Lidia Vatteroni, Marialinda Pistello, Mauro Virdis, Agostino Bonino, Ferruccio Brunetto, Maurizia Rossana |
author_sort | Colombatto, Piero |
collection | PubMed |
description | Direct-acting antivirals (DAAs) for hepatitis C virus (HCV) may induce hepatitis B virus (HBV) reactivations in co-infected patients, whose dynamics and outcomes could depend on the phase of HBV infection. We investigated HBsAg and HBV-DNA kinetics in fifteen untreated HBeAg Negative Infection (ENI) (4F-11M, 62.1y) and eight Nucleos(t)ide Analogs (NAs) treated Chronic Hepatitis B (CHB) (3F-6M, 54.8y) with HCV co-infection, receiving DAAs-regimens including Sofosbuvir (13) or not (10). All achieved a sustained virologic response (SVR) and normalized alanine-aminotransferase (ALT). At the direct acting antivirals’ (DAAs) baseline (BL), the HBV-DNA was undetectable (<6 IU/mL) in eight ENI and all CHB, the mean Log-HBsAg was lower in ENI than CHB (0.88 vs. 2.42, p = 0.035). During DAAs, HBV-DNA increased in untreated ENI by >1 Log in five and became detectable in two. Accordingly, mean BL Log-HBV-DNA (0.89) increased at week-4 (1.78; p = 0.100) and at the end of therapy (1.57; p = 0.104). Mean Log-HBsAg decreased at week-4 in ENI (from 0.88 to 0.55; p = 0.020) and CHB (from 2.42 to 2.15; p = 0.015). After DAAs, the HBsAg returned to pre-treatment levels in CHB, but not in ENI (six cleared HBsAg). Female gender and SOF were associated with a greater HBsAg decline. In conclusion, HBV reactivations during DAAs in HCV co-infected ENI caused moderate increases of HBV-DNA without ALT elevations. The concomitant HBsAg decline, although significant, did not modify individual pre-treatment profiles. |
format | Online Article Text |
id | pubmed-8911219 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89112192022-03-11 Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy Colombatto, Piero Palmisano, Elena Ricco, Gabriele Cavallone, Daniela Oliveri, Filippo Coco, Barbara Salvati, Antonio Romagnoli, Veronica Surace, Lidia Vatteroni, Marialinda Pistello, Mauro Virdis, Agostino Bonino, Ferruccio Brunetto, Maurizia Rossana J Clin Med Article Direct-acting antivirals (DAAs) for hepatitis C virus (HCV) may induce hepatitis B virus (HBV) reactivations in co-infected patients, whose dynamics and outcomes could depend on the phase of HBV infection. We investigated HBsAg and HBV-DNA kinetics in fifteen untreated HBeAg Negative Infection (ENI) (4F-11M, 62.1y) and eight Nucleos(t)ide Analogs (NAs) treated Chronic Hepatitis B (CHB) (3F-6M, 54.8y) with HCV co-infection, receiving DAAs-regimens including Sofosbuvir (13) or not (10). All achieved a sustained virologic response (SVR) and normalized alanine-aminotransferase (ALT). At the direct acting antivirals’ (DAAs) baseline (BL), the HBV-DNA was undetectable (<6 IU/mL) in eight ENI and all CHB, the mean Log-HBsAg was lower in ENI than CHB (0.88 vs. 2.42, p = 0.035). During DAAs, HBV-DNA increased in untreated ENI by >1 Log in five and became detectable in two. Accordingly, mean BL Log-HBV-DNA (0.89) increased at week-4 (1.78; p = 0.100) and at the end of therapy (1.57; p = 0.104). Mean Log-HBsAg decreased at week-4 in ENI (from 0.88 to 0.55; p = 0.020) and CHB (from 2.42 to 2.15; p = 0.015). After DAAs, the HBsAg returned to pre-treatment levels in CHB, but not in ENI (six cleared HBsAg). Female gender and SOF were associated with a greater HBsAg decline. In conclusion, HBV reactivations during DAAs in HCV co-infected ENI caused moderate increases of HBV-DNA without ALT elevations. The concomitant HBsAg decline, although significant, did not modify individual pre-treatment profiles. MDPI 2022-03-04 /pmc/articles/PMC8911219/ /pubmed/35268497 http://dx.doi.org/10.3390/jcm11051406 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Colombatto, Piero Palmisano, Elena Ricco, Gabriele Cavallone, Daniela Oliveri, Filippo Coco, Barbara Salvati, Antonio Romagnoli, Veronica Surace, Lidia Vatteroni, Marialinda Pistello, Mauro Virdis, Agostino Bonino, Ferruccio Brunetto, Maurizia Rossana Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy |
title | Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy |
title_full | Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy |
title_fullStr | Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy |
title_full_unstemmed | Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy |
title_short | Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy |
title_sort | different kinetics of hbv-dna and hbsag in hcv coinfected patients during daas therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911219/ https://www.ncbi.nlm.nih.gov/pubmed/35268497 http://dx.doi.org/10.3390/jcm11051406 |
work_keys_str_mv | AT colombattopiero differentkineticsofhbvdnaandhbsaginhcvcoinfectedpatientsduringdaastherapy AT palmisanoelena differentkineticsofhbvdnaandhbsaginhcvcoinfectedpatientsduringdaastherapy AT riccogabriele differentkineticsofhbvdnaandhbsaginhcvcoinfectedpatientsduringdaastherapy AT cavallonedaniela differentkineticsofhbvdnaandhbsaginhcvcoinfectedpatientsduringdaastherapy AT oliverifilippo differentkineticsofhbvdnaandhbsaginhcvcoinfectedpatientsduringdaastherapy AT cocobarbara differentkineticsofhbvdnaandhbsaginhcvcoinfectedpatientsduringdaastherapy AT salvatiantonio differentkineticsofhbvdnaandhbsaginhcvcoinfectedpatientsduringdaastherapy AT romagnoliveronica differentkineticsofhbvdnaandhbsaginhcvcoinfectedpatientsduringdaastherapy AT suracelidia differentkineticsofhbvdnaandhbsaginhcvcoinfectedpatientsduringdaastherapy AT vatteronimarialinda differentkineticsofhbvdnaandhbsaginhcvcoinfectedpatientsduringdaastherapy AT pistellomauro differentkineticsofhbvdnaandhbsaginhcvcoinfectedpatientsduringdaastherapy AT virdisagostino differentkineticsofhbvdnaandhbsaginhcvcoinfectedpatientsduringdaastherapy AT boninoferruccio differentkineticsofhbvdnaandhbsaginhcvcoinfectedpatientsduringdaastherapy AT brunettomauriziarossana differentkineticsofhbvdnaandhbsaginhcvcoinfectedpatientsduringdaastherapy |